Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
TransCode Therapeutics ( (RNAZ) ) has issued an update.
On May 2, 2025, TransCode Therapeutics announced that its stockholders approved a 1-for-28 reverse stock split to meet Nasdaq’s minimum bid price requirements. This move, aimed at increasing the per-share trading price, will reduce the number of outstanding shares from 23,341,336 to approximately 833,620. The reverse stock split will automatically convert twenty-eight current shares into one new share, with no fractional shares issued. The effective date is yet to be determined, and the company will announce it at least two days before implementation. This strategic decision is significant for maintaining the company’s Nasdaq listing and potentially improving its market position.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics. Utilizing its proprietary TTX nanoparticle platform, the company aims to defeat cancer by designing and delivering RNA-based treatments. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. TransCode is also developing a portfolio of RNA therapeutic candidates to address various genetic targets relevant to cancer treatment.
YTD Price Performance: -84.02%
Average Trading Volume: 9,237,400
Technical Sentiment Signal: Buy
Current Market Cap: $13.16M
Learn more about RNAZ stock on TipRanks’ Stock Analysis page.